PneumoniaNCT01606267
Evaluation of Integrated Community Case Management in Ethiopia
A study testing health systems intervention: HEP+ICCM in people with Pneumonia, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Ethiopia.
Trial summary
The purpose of this study is to to measure the effect of the HEP+ICCM program relative to routine HEP approach in rural Ethiopia on changes in coverage of case management of common childhood illnesses and severe acute malnutrition, reductions in mortality among children under the age of five, and improvements in… Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Pneumonia
- What is being tested?
- health systems intervention: HEP+ICCM
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 607,770 participants
- Where
- 1 siteEthiopia
- Study dates
- Dec 2010to May 2013
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Surveys:
- Members of households in evaluation woredas in Jimma and West Haraghe zones of Ethiopia.
- Quality of Care Implementation snapshot:
- Health posts: All functional health posts in the study zones will be included in the sampling frame. In cases where an HEW is providing services, but an official health post structure has not been constructed, the HEW's primary location for providing case management services will be considered as the health post.
- HEWs: All HEWs providing case management services in selected health posts will be included.
- Patients must meet the following criteria:
- Between 2 and 59 months of age;
- Described as sick by the caretaker. Sick children must have at least one of the following complaints: signs or symptoms of severe illness (change in consciousness/lethargy, convulsions, vomiting everything, not eating or drinking); fever/malaria; cough, fast/difficulty breathing, pneumonia; diarrhea/vomiting; ear problem; measles; nutrition or feeding problems;
Who cannot join
- Surveys:
- Members of households NOT residing in the evaluation woredas in Jimma and West Haraghe zones of Ethiopia.
- Members of households in urban communities.
- Participant does not consent to study procedures
- Quality of Care Implementation snapshot:
- Non-functional health posts
Show all 11Show fewer
- HEW does not consent to procedure.
- Patients will be excluded from the study:
- If this is not the initial consultation for the current illness episode: patient has been seen at the health post, by the HEWs (including home/community).
- Patient is younger than 2 months or older than 59 months.
- Caretaker does not consent to procedure.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Independent Prospective Evaluation of Integrated Community Case Management and Development and Implementation of a Method for Real-time Mortality Monitoring in the Oromia Region, Ethiopia
The purpose of this study is to to measure the effect of the HEP+ICCM program relative to routine HEP approach in rural Ethiopia on changes in coverage of case management of common childhood illnesses and severe acute malnutrition, reductions in mortality among children under the age of five, and improvements in nutritional status using a rigorous evaluation design.
Read the detailed description
STUDY BACKGROUND AND RATIONAL Most low-income countries are making slow progress in addressing childhood mortality - too slow to achieve the fourth Millennium Development Goal by 2015. Countries, donors and development agencies are responding to the situation by redoubling efforts to stimulate and support child survival activities in countries, particularly in Africa. The Catalytic Initiative to Save a Million Lives (CI) is a partnership between donor agencies committed to accelerate progress toward MDGs 4 and 5 through support of scale-up of proven high impact interventions. UNICEF and the Canadian International Development Agency (CIDA), as part of the CI, are undertaking a major initiative to reduce mortality among children less than five years of age in several countries in sub-Saharan Africa, including Ethiopia.
Ethiopia has a high under-five mortality rate, estimated at 123 per 1000 live births by the 2005 Demographic and Health Survey. The country has made a commitment to achieve the MDG 4 target of a two-thirds reduction in mortality by 2015 as reflected through the launching of the national Health Extension Program (HEP) in 2004, with continued support from UNICEF and CI funding. The key program strategy is to train and support approximately 30,000 Health Extension Workers (HEWs) to provide promotive, preventive, and selected curative health care services at the community level. Previously, the HEWs treated diarrhea with ORS and malaria with rapid diagnostic kits and ACTs; pneumonia cases were referred to health centers.
Ethiopia has recently adopted a policy to expand management of pneumonia among children under-five with antibiotics to communities through HEWs. This provides a unique opportunity to accelerate increases in coverage of treatment of pneumonia, which is one of the greatest killers of children under-five in Ethiopia. This expansion, when combined with the existing community management of malaria, diarrhea and severe acute malnutrition, is referred to as integrated community case management (HEP+ICCM) and is largely supported through the Catalytic Initiative by CIDA and UNICEF and will focus on its first stage on five regions of the country: Amhara, Benishangul-Gumaz, Oromia, SNNP and Tigray. The leading strategy of the HEP+ICCM initiative is to increase the capacity of the HEWs to effectively assess, classify, and manage the leading causes of preventable child mortality including pneumonia, malaria, diarrhea, and severe acute malnutrition. In the focus regions, plans have been developed to introduce CCM of childhood pneumonia with cotrimoxazole and diarrhea with ORS and zinc, malaria with ACTs, and malnutrition with therapeutic feeding. The program plans to conduct refresher trainings of HEWs and their supervisors, strengthen supervision, logistical support and the ICCM system overall. The initial implementation will start in August 2010 and to be phased in Oromia region.
The effectiveness of the ICCM varies across specific country contexts and depends on the strength of implementation. It is therefore essential to evaluate the effectiveness of the scale-up strategy to provide a basis for future program improvement and global evidence on effective strategies for accelerating reductions in under-five mortality.
OBJECTIVES The Institute for International Programs at the Johns Hopkins University Bloomberg School of Public Health (IIP-JHU) has been commissioned by CIDA and UNICEF to conduct an independent prospective evaluation of the HEP+ICCM.
This study objective is to conduct a full prospective evaluation of the impact of the Ethiopian HEP+ICCM of common childhood illnesses implemented through HEWs on mortality and nutritional status of children under the age of five.
The specific objectives of the study are:
- To measure the effect of the HEP+ICCM program relative to routine HEP approach in the country over an 18 month period on changes in coverage of case management of common childhood illnesses and severe acute malnutrition, reductions in mortality among children under the age of five, and improvements in nutritional status using a rigorous evaluation design; ii. To track program implementation inputs, processes, outputs and contextual factors; and iii. To measure implementation strength and assess the quality of child health care.
METHODOLOGY In Oromia region, implementation of the HEP+ICCM program will be phased allowing the possibility to identify comparison areas for the evaluation. The prospective evaluation will use a cluster randomized design with stratification by zone, within which woredas are randomly assigned to intervention and comparison arms using a restricted randomization procedure. Coverage of childhood interventions will be measured at baseline and end-line with a midterm "quality of care implementation snapshot" to assess the strength of implementation. Mortality estimates for both the intervention and comparison woredas will be generated retrospectively through the end-line household survey. Program implementation and contextual factors will be documented throughout the evaluation period.
The evaluation will be focused the Jimma and West Hararge zones. Woredas within the two evaluation zones will be randomly assigned to intervention and comparison areas. Intervention areas are referred to as phase 1 area and comparison areas referred to as phase 2 areas. The phase 1 and 2 woredas will be randomly assigned through an adapted, restricted randomization process, balanced by the presence of malaria, food security and the zone. Urban areas were excluded since the urban HEP is a recent addition and implemented differently. In Jimma zone, the seventeen woredas will be divided into nine phase 1 woredas and eight phase 2 woredas. In West Haraghe zone, there will be seven woredas in phase 1 and phase 2 areas.
The ORHB has committed to at least an 18-month phase-in between the identified intervention and comparison areas in these two areas. Phase 1 woredas will implement HEP+ICCM while the Phase 2 woredas will continue to offer services included in the routine HEP. Phase 1 implementation in the two evaluation zones will begin in February 2011, following the baseline coverage survey.
DATA SOURCES Household Surveys: The primary data for the evaluation will come from baseline and end-line household surveys. The baseline survey was conducted in January - February 2011 and the end-line survey will be conducted 18 months following the end of the HEW training as part of phase one. These surveys will measure coverage of the child health interventions of interest and nutritional status among children under five. The end-line survey will include, in addition to coverage measures, a full birth history for women 15-49 years old to measure retrospectively mortality among children under five. Partners report that phase one implementation was completed in July 2011; therefore the end-line survey is planned for January 2013.
For the baseline survey, we estimate that 3,700 households (1850 in each arm) are required to detect a change in coverage indicators between baseline and end-line. For the end-line survey, sample size of households is calculated to detect a difference in differences of 20 percentage point in under-five mortality between intervention and comparison areas with 80% power. We estimate a conservative sample of about 15,157 households in each arm of the study will be required, making a total sample size of 30,314 households.
Measurement of implementation strength and assessment of quality of child health care data: A community-level survey of HEWs is planned to provide a "snapshot" of HEP +ICCM implementation strength in the two evaluation zones. The data collected will comprise core indicators of implementation strength, as well as indicators on demand-generation activities, utilization and the quality of services provided by HEWs.
The study will sample functional 104 health posts in the intervention areas and 46 in the comparison areas. Study participants will include: 1) HEWs performing case management of childhood illnesses, 2) sick children 2-59 months of age presenting at health posts for consultations and their caretakers and 3) sick children 2-59 months in the communities surrounding health posts.
ANALYSIS The main analysis of the data will involve comparison of trends in coverage and impact indicators between intervention and comparison arms, using appropriate statistical models that adjust for clustering at cluster level. Adequacy of implementation in each arm of the evaluation will be determined using data from baseline surveys, process documentation data and the implementation snapshot survey.
Using data from the end-line survey, under-five mortality will be computed on 18-month period before the baseline survey (which will represent the baseline under-five mortality) and on 18-month period after full implementation (the end-line under-five mortality). Precaution will be taken to measure the end-line mortality only on period starting from time when full implementation (training and deployment of HEWs with drugs) has been completed. Full implementation in intervention woredas was achieved in July 2011, six months after the completion of the baseline survey.
The first level of analysis will assess "intention to treat", which consists of analyzing the data from the intervention and comparison arms as per the start-up design. This analysis will compare changes between baseline and end-line in under-five mortality rates as well as nutritional status among children under-five in the intervention and comparison areas. Difference in differences analysis will be conducted to estimate the impact of the ICCM on mortality. Proportion hazard models will also be applied to control for possible differences in baseline characteristics and contextual factors.
An important secondary objective of the HEP+ICCM is to increase equity in access to high impact, cost-effective preventative and curative interventions. The evaluation team will assess changes in inequalities associated with the implementation of the HEP+ICCM program interventions by examining project outcomes and impact across socioeconomic and demographic subgroups.
- Conditions
- Pneumonia
- Being tested
- health systems intervention: HEP+ICCM
- Keywords
- Integrated Community Case Management, Pneumonia, Ethiopia
- Medical subject headings
- Pneumonia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
health systems intervention: HEP+ICCMOther
In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
| Study group | Role | What they receive |
|---|---|---|
| Routine HEP | No intervention | This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities. |
| HEP+ICCM | Experimental | This arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities. Receives: Other: health systems intervention: HEP+ICCM |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality rate among children under-five (0-59 months)
Measured: Over a 12 and 18 month period
Secondary outcomes (5)
Mortality rate among children 1-59 months
Measured: Over a 12 and 18 month period
Malnutrition of under-five children (wasting, stunting and underweight rates)
Measured: Measured at 0 and 18 months
Treatment coverage of childhood diarrhea, malaria, pneumonia and malnutrition
Measured: Measured at 0 and 18 months
Care-seeking coverage for childhood diarrhea, malaria, pneumonia and malnutrition
Measured: Measured at 0 and 18 months
Proportion of sick children observed who did not need urgent referral with a validated classification of pneumonia, malaria, diarrhea and/or SAM for whom all medications received correctly matched the validated prescription
Measured: Measured once at 10 months (midterm)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 May 2012 (estimated)
- Study startDec 2010
- Primary completionMay 2013
- Study completionMay 2013
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for PneumoniaStudies of the same condition, open and under way.
- More trials run by Johns Hopkins Bloomberg School of Public HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 607,770 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- Canadian International Development Agency, UNICEF
- Responsible party
- Sponsor
- Investigators
- Robert Black, MD, MPH, Principal investigator, Johns Hopkins Bloomberg School of Public HealthAgbessi Amouzou, PhD, Principal investigator, Johns Hopkins Bloomberg School of Public Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01606267
- Sponsor's protocol ID
- Grant # 109947
- Status last verified
- Apr 2018
- First submitted
- 18 May 2012
- Last updated
- 23 Apr 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 23 Apr 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Independent Prospective Evaluation of Integrated Community Case Management and Development and Implementation of a Method for Real-time Mortality Monitoring in the Oromia Region, Ethiopia
- ClinicalTrials.gov ID
- NCT01606267
- Acronym / sponsor ID
- Grant # 109947
- Conditions
- Pneumonia
- Keywords
- Integrated Community Case Management, Pneumonia, Ethiopia
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 607,770 participants (actual)
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthUniversity, hospital or other
- Collaborators
- Canadian International Development Agency, UNICEF
- Study start
- Dec 2010 (actual)
- Primary completion
- May 2013 (actual)
- Study completion
- May 2013 (actual)
- First posted
- 25 May 2012 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to to measure the effect of the HEP+ICCM program relative to routine HEP approach in rural Ethiopia on changes in coverage of case management of common childhood illnesses and severe acute malnutrition, reductions in mortality among children under the age of five, and improvements in nutritional status using a rigorous evaluation design.
Detailed description
STUDY BACKGROUND AND RATIONAL Most low-income countries are making slow progress in addressing childhood mortality - too slow to achieve the fourth Millennium Development Goal by 2015. Countries, donors and development agencies are responding to the situation by redoubling efforts to stimulate and support child survival activities in countries, particularly in Africa. The Catalytic Initiative to Save a Million Lives (CI) is a partnership between donor agencies committed to accelerate progress toward MDGs 4 and 5 through support of scale-up of proven high impact interventions. UNICEF and the Canadian International Development Agency (CIDA), as part of the CI, are undertaking a major initiative to reduce mortality among children less than five years of age in several countries in sub-Saharan Africa, including Ethiopia.
Ethiopia has a high under-five mortality rate, estimated at 123 per 1000 live births by the 2005 Demographic and Health Survey. The country has made a commitment to achieve the MDG 4 target of a two-thirds reduction in mortality by 2015 as reflected through the launching of the national Health Extension Program (HEP) in 2004, with continued support from UNICEF and CI funding. The key program strategy is to train and support approximately 30,000 Health Extension Workers (HEWs) to provide promotive, preventive, and selected curative health care services at the community level. Previously, the HEWs treated diarrhea with ORS and malaria with rapid diagnostic kits and ACTs; pneumonia cases were referred to health centers.
Ethiopia has recently adopted a policy to expand management of pneumonia among children under-five with antibiotics to communities through HEWs. This provides a unique opportunity to accelerate increases in coverage of treatment of pneumonia, which is one of the greatest killers of children under-five in Ethiopia. This expansion, when combined with the existing community management of malaria, diarrhea and severe acute malnutrition, is referred to as integrated community case management (HEP+ICCM) and is largely supported through the Catalytic Initiative by CIDA and UNICEF and will focus on its first stage on five regions of the country: Amhara, Benishangul-Gumaz, Oromia, SNNP and Tigray. The leading strategy of the HEP+ICCM initiative is to increase the capacity of the HEWs to effectively assess, classify, and manage the leading causes of preventable child mortality including pneumonia, malaria, diarrhea, and severe acute malnutrition. In the focus regions, plans have been developed to introduce CCM of childhood pneumonia with cotrimoxazole and diarrhea with ORS and zinc, malaria with ACTs, and malnutrition with therapeutic feeding. The program plans to conduct refresher trainings of HEWs and their supervisors, strengthen supervision, logistical support and the ICCM system overall. The initial implementation will start in August 2010 and to be phased in Oromia region.
The effectiveness of the ICCM varies across specific country contexts and depends on the strength of implementation. It is therefore essential to evaluate the effectiveness of the scale-up strategy to provide a basis for future program improvement and global evidence on effective strategies for accelerating reductions in under-five mortality.
OBJECTIVES The Institute for International Programs at the Johns Hopkins University Bloomberg School of Public Health (IIP-JHU) has been commissioned by CIDA and UNICEF to conduct an independent prospective evaluation of the HEP+ICCM.
This study objective is to conduct a full prospective evaluation of the impact of the Ethiopian HEP+ICCM of common childhood illnesses implemented through HEWs on mortality and nutritional status of children under the age of five.
The specific objectives of the study are:
- To measure the effect of the HEP+ICCM program relative to routine HEP approach in the country over an 18 month period on changes in coverage of case management of common childhood illnesses and severe acute malnutrition, reductions in mortality among children under the age of five, and improvements in nutritional status using a rigorous evaluation design; ii. To track program implementation inputs, processes, outputs and contextual factors; and iii. To measure implementation strength and assess the quality of child health care.
METHODOLOGY In Oromia region, implementation of the HEP+ICCM program will be phased allowing the possibility to identify comparison areas for the evaluation. The prospective evaluation will use a cluster randomized design with stratification by zone, within which woredas are randomly assigned to intervention and comparison arms using a restricted randomization procedure. Coverage of childhood interventions will be measured at baseline and end-line with a midterm "quality of care implementation snapshot" to assess the strength of implementation. Mortality estimates for both the intervention and comparison woredas will be generated retrospectively through the end-line household survey. Program implementation and contextual factors will be documented throughout the evaluation period.
The evaluation will be focused the Jimma and West Hararge zones. Woredas within the two evaluation zones will be randomly assigned to intervention and comparison areas. Intervention areas are referred to as phase 1 area and comparison areas referred to as phase 2 areas. The phase 1 and 2 woredas will be randomly assigned through an adapted, restricted randomization process, balanced by the presence of malaria, food security and the zone. Urban areas were excluded since the urban HEP is a recent addition and implemented differently. In Jimma zone, the seventeen woredas will be divided into nine phase 1 woredas and eight phase 2 woredas. In West Haraghe zone, there will be seven woredas in phase 1 and phase 2 areas.
The ORHB has committed to at least an 18-month phase-in between the identified intervention and comparison areas in these two areas. Phase 1 woredas will implement HEP+ICCM while the Phase 2 woredas will continue to offer services included in the routine HEP. Phase 1 implementation in the two evaluation zones will begin in February 2011, following the baseline coverage survey.
DATA SOURCES Household Surveys: The primary data for the evaluation will come from baseline and end-line household surveys. The baseline survey was conducted in January - February 2011 and the end-line survey will be conducted 18 months following the end of the HEW training as part of phase one. These surveys will measure coverage of the child health interventions of interest and nutritional status among children under five. The end-line survey will include, in addition to coverage measures, a full birth history for women 15-49 years old to measure retrospectively mortality among children under five. Partners report that phase one implementation was completed in July 2011; therefore the end-line survey is planned for January 2013.
For the baseline survey, we estimate that 3,700 households (1850 in each arm) are required to detect a change in coverage indicators between baseline and end-line. For the end-line survey, sample size of households is calculated to detect a difference in differences of 20 percentage point in under-five mortality between intervention and comparison areas with 80% power. We estimate a conservative sample of about 15,157 households in each arm of the study will be required, making a total sample size of 30,314 households.
Measurement of implementation strength and assessment of quality of child health care data: A community-level survey of HEWs is planned to provide a "snapshot" of HEP +ICCM implementation strength in the two evaluation zones. The data collected will comprise core indicators of implementation strength, as well as indicators on demand-generation activities, utilization and the quality of services provided by HEWs.
The study will sample functional 104 health posts in the intervention areas and 46 in the comparison areas. Study participants will include: 1) HEWs performing case management of childhood illnesses, 2) sick children 2-59 months of age presenting at health posts for consultations and their caretakers and 3) sick children 2-59 months in the communities surrounding health posts.
ANALYSIS The main analysis of the data will involve comparison of trends in coverage and impact indicators between intervention and comparison arms, using appropriate statistical models that adjust for clustering at cluster level. Adequacy of implementation in each arm of the evaluation will be determined using data from baseline surveys, process documentation data and the implementation snapshot survey.
Using data from the end-line survey, under-five mortality will be computed on 18-month period before the baseline survey (which will represent the baseline under-five mortality) and on 18-month period after full implementation (the end-line under-five mortality). Precaution will be taken to measure the end-line mortality only on period starting from time when full implementation (training and deployment of HEWs with drugs) has been completed. Full implementation in intervention woredas was achieved in July 2011, six months after the completion of the baseline survey.
The first level of analysis will assess "intention to treat", which consists of analyzing the data from the intervention and comparison arms as per the start-up design. This analysis will compare changes between baseline and end-line in under-five mortality rates as well as nutritional status among children under-five in the intervention and comparison areas. Difference in differences analysis will be conducted to estimate the impact of the ICCM on mortality. Proportion hazard models will also be applied to control for possible differences in baseline characteristics and contextual factors.
An important secondary objective of the HEP+ICCM is to increase equity in access to high impact, cost-effective preventative and curative interventions. The evaluation team will assess changes in inequalities associated with the implementation of the HEP+ICCM program interventions by examining project outcomes and impact across socioeconomic and demographic subgroups.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Routine HEP | No intervention | –This arm includes routine care provided under the health extension program provided to rural Ethiopian villages with limited access to health facilities. |
| HEP+ICCM | Experimental | Other: health systems intervention: HEP+ICCMThis arm includes routine care provided under the Health Extension Program plus the HEWs will be assessing and treating childhood pneumonia cases in rural Ethiopian villages with limited access to health facilities. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (8 listed)
- Surveys:
- Quality of Care Implementation snapshot:
Key exclusion criteria (11 listed)
- Surveys:
- Quality of Care Implementation snapshot:
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| health systems intervention: HEP+ICCMIn the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall. | Other | HEP+ICCM |
Primary outcome
Mortality rate among children under-five (0-59 months)
Time frame: Over a 12 and 18 month period
5 secondary outcomes
Mortality rate among children 1-59 months
Time frame: Over a 12 and 18 month period
Malnutrition of under-five children (wasting, stunting and underweight rates)
Time frame: Measured at 0 and 18 months
Treatment coverage of childhood diarrhea, malaria, pneumonia and malnutrition
Time frame: Measured at 0 and 18 months
Care-seeking coverage for childhood diarrhea, malaria, pneumonia and malnutrition
Time frame: Measured at 0 and 18 months
Proportion of sick children observed who did not need urgent referral with a validated classification of pneumonia, malaria, diarrhea and/or SAM for whom all medications received correctly matched the validated prescription
Time frame: Measured once at 10 months (midterm)
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 23 Apr 2018.
Related trials for Pneumonia
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Not yet recruitingPhase 2/3
A Pivotal Safety and Immunogenicity GBS-NN/NN2 Vaccine Maternal Immunisation Trial
Streptococcus Agalactiae Infection, Neonatal Sepsis
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Enrolling by invitation
Personalized Ventilator Settings for Patients on ECMO
Acute Respiratory Distress Syndrome (ARDS), Extracorporeal Membrane Oxygenation
Not yet recruiting
Expanded Diagnostic Strategy in Older Adults Hospitalized With Community-Acquired Acute Respiratory Infection
Acute Respiratory Infection
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert Black, MD, MPH principal investigator
Johns Hopkins Bloomberg School of Public Health
Agbessi Amouzou, PhD principal investigator
Johns Hopkins Bloomberg School of Public Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing health systems intervention: HEP+ICCM in people with Pneumonia, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 23 Apr 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality rate among children under-five (0-59 months) (time frame: Over a 12 and 18 month period). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Apr 2018.